Identify the Atrophy of Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging Using Morphometric MRI

Xiangyu Ma1, Zhaoxia Li2, Bin Jing1

  • 1School of Biomedical Engineering, Capital Medical University Beijing, China.

Insights

This study introduces a new MRI method to measure brain atrophy in Alzheimer's disease (AD) and mild cognitive impairment (MCI). The approach accurately detects structural changes, aiding in early AD diagnosis and progression tracking.

Area of Science:

  • Neuroimaging
  • Neurology
  • Medical Diagnostics

Background:

  • Medial temporal lobe (MTL) atrophy assessment is crucial for Alzheimer's disease (AD) diagnosis and progression monitoring.
  • Gray matter volume (GMV) and cortical thickness are key indicators of brain atrophy.

Purpose of the Study:

  • To develop and validate a morphometric MRI analysis method for quantifying GMV and cortical thickness changes in AD, MCI, and normal elderly individuals.
  • To explore cross-sectional differences and longitudinal changes in these morphometric indicators within the MTL.

Main Methods:

  • Utilized high-resolution 3D MRI data from the ADNI database.
  • Employed SPM8 plus DARTEL for preprocessing and calculated z-score maps for GMV and cortical thickness decline.
  • Defined MTL-specific atrophy indicators and used Kruskal-Wallis tests and Support Vector Machines (SVM) for statistical analysis and prediction.

Main Results:

  • GMV and cortical thickness decline showed a significant increase from normal controls (NC) to MCI and AD.
  • SVM models achieved high discrimination accuracies: 92.7% (AD vs. NC), 91.7% (MCI vs. NC), and 78.4% (AD vs. MCI).
  • The method effectively identified atrophy rate differences across groups in longitudinal analysis.

Conclusions:

  • The proposed MRI-based morphometric analysis provides an automatic and efficient approach for early AD diagnosis.
  • This method aids in accurately tracking disease progression by quantifying MTL structural changes.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...